following a full submission:
buprenorphine implant (Sixmo®) is accepted for use within NHSScotland.
Indication under review: for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.
Buprenorphine implant was non-inferior to buprenorphine-naloxone sublingual tablets for controlling illicit drug use in patients transferred from stable daily doses of sublingual buprenorphine up to 8mg.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- buprenorphine implant (Sixmo)
- SMC ID:
- SMC2372
- Indication:
Substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.
- Pharmaceutical company
- Accord Healthcare
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 December 2021